SCHEMBL723364

SCHEMBL723364

Cn1cc(-c2ccnc3cc(-c4ccc5c(c4)ncn5C)oc23)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT1 P04628 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
MET P08581 3/20 0.38
AURKB Q96GD4 3/20 0.37
AURKA O14965 2/20 0.37
INCENP Q9NQS7 2/20 0.37
TPX2 Q9ULW0 2/20 0.37
LRRK2 Q5S007 3/20 0.37
ALK Q9UM73 1/20 0.37
TGFBR1 P36897 2/20 0.36
TGFBR2 P37173 2/20 0.36
PRKAB2 O43741 1/20 0.36
ABL1 P00519 1/20 0.36
CSF1R P07333 1/20 0.36
LYN P07948 1/20 0.36
PRKAG1 P54619 1/20 0.36
SIK1 P57059 1/20 0.36
PRKAA1 Q13131 1/20 0.36
SIK2 Q9H0K1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10268949 0.85 AURKB (0.46) METAURKBAURKAINCENPTPX2
SCHEMBL725127 0.83 WNT1 (0.42) WNT1GSK3BDYRK1AMETAURKB
SCHEMBL16817167 0.82 LRRK2 (0.45) METAURKBAURKAINCENPTPX2
SCHEMBL724102 0.82 AURKB (0.38) METAURKBAURKAINCENPTPX2
SCHEMBL10268110 0.81 MET (0.44) METAURKBAURKAINCENPTPX2
SCHEMBL722397 0.80 AURKB (0.44) METAURKBAURKAINCENPTPX2
SCHEMBL723727 0.80 FYN (0.40) METAURKBAURKAINCENPTPX2
SCHEMBL725506 0.79 KCNH2 (0.43) METAURKBAURKAINCENPTPX2
SCHEMBL722106 0.79 MTOR (0.47) METAURKBAURKAINCENPTPX2
SCHEMBL724888 0.78 ACVR2A (0.48) AURKBAURKAINCENPTPX2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB WNT1 2800/4885GSK3B 1801/4885DYRK1A 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.